Sreekanth Chalasani (Salk Insitute of Biological Studies; CA, USA) discusses early work into the use of ultrasound for nerve manipulation, a technique termed ‘sonogenetics’.
Browsing: Movement disorders
This Epigenomics review explores the role of UBE3A in the regulation of protein stability and transcription as well as current understanding of UBE3A imprinting in neurons responsible for the development of a range of neurodevelopmental disorders.
A small molecule inhibitor, termed dipraglurant, has been granted orphan drug designation for Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease by the US FDA.
Andrés Miguez & Jordi Alberch (University of Barcelona, Spain) discuss their exceptional work on the potential efficacy of the Multiple Sclerosis drug, Fingolimod, in treating cognitive deficits in Huntington’s disease.
Jose Spring gives us a brief overview of her work investigating therapeutic gardening for patients with neurodisability and dementia in both the UK and Scandinavia.
The use of dopamine agonists for Parkinson’s treatment is often associated with unwanted side effects. This review identifies strategies for managing or avoiding these effects and discusses future needs to improve the understanding of these phenomena.
This article investigates the neuroprotective potential of systemic CD34+ human cord blood cells (hCBCs) in a 6-hydroxydopamine rat model of Parkinson’s disease.
A recent investigation suggests that a drug commonly used to treat liver disease – ursodeoxycholic acid – could slow the progression of Parkinson’s disease.
New research has shed light on the role of C9orf72 within the cells of patients with amyotrophic lateral sclerosis
ISCO develop a parthenogenesis stem cell technology which could potentially avoid the limiting immune-response issues in regenerative medicine.